Table 1.

FDA-approved medications for MM from 2006 to 2013.

Drug	Year	Treatment	Adverse Effects	Refs.
Thalidomide	2006	NDMM	somnolence, constipation, neuropathy, VTE, and rash	[48,49]
Lenalidomide	2006	Received one prior therapy	neutropenia, thrombocytopenia, leukopenia, lymphopenia, febrile neutropenia, deep vein thrombosis, pulmonary embolism, atrial fibrillation, constipation, diarrhea, fatigue, pneumonia, hypokalemia, hypocalcemia, muscle weakness, neuropathy, and depression	[50]
Doxorubicin	2007	RRMM	thrombocytopenia, neutropenia, anemia, fatigue, pyrexia, nausea, vomiting, mucositis/stomatitis diarrhea, and hand foot syndrome	[49,51]
Bortezomib	2008	NDMM	asthenic conditions, diarrhea, constipation, PSN, vomiting, nausea psychiatric disorders, pyrexia, anorexia, thrombocytopenia, leukopenia, neuralgia, neutropenia, and anemia	[49,52]
Plerixafor	2008	MM	diarrhea, vomiting, nausea, fatigue, headache, injection site reactions, dizziness, and arthralgia	[49,53]
Carfilzomib	2012	RRMM	fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, pyrexia, pneumonia, ARF, pyrexia, and CHF	[54]
Pomalidomide	2013	RRMM	asthenia, fatigue, neutropenia, anemia, constipation, diarrhea, nausea, URTI, dyspnea, back pain, and pyrexia	[55]

NDMM: newly diagnosed multiple myeloma; RRMM: relapsed/refractory multiple myeloma; NTE: non-transplant-eligible; TE: transplant eligible; Td: thalidomide, dexamethasone; Rd: lenalidomide, dexamethasone; V: bortezomib; PLD-V: pegylated liposomal doxorubicin, bortezomib; MP: melphalan, prednisone; VMP: bortezomib, melphalan, prednisone; G-CSF: granulocyte-colony-stimulating factor; Plerix-G-CSF: plerixafor, granulocyte-colony-stimulating factor; Pd: pomalidomide, dexamethasone; VTE: venous thromboembolism; PSN: Peripheral sensory neuropathy; ARF: acute renal failure; CHF: congestive heart failure; URTI: Upper respiratory tract infection.